Northern Trust
ALDX icon

Northern Trust’s Aldeyra Therapeutics ALDX Stock Holding History

Northern Trust’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$633K Sell
374,812
-4,593
-1% -$20.1K ﹤0.01% 3520
2025
Q4 		$1.97M Sell
379,405
-28,555
-7% -$147K ﹤0.01% 3010
2025
Q3 		$2.13M Buy
407,960
+4,009
+1% +$20.9K ﹤0.01% 3010
2025
Q2 		$1.55M Buy
403,951
+14,369
+4% +$37.1K ﹤0.01% 3139
2025
Q1 		$2.24M Sell
389,582
-15,935
-4% -$94.2K ﹤0.01% 2860
2024
Q4 		$2.02M Buy
405,517
+16,894
+4% +$86.7K ﹤0.01% 3015
2024
Q3 		$2.09M Buy
388,623
+3,116
+0.8% +$14.8K ﹤0.01% 2974
2024
Q2 		$1.28M Sell
385,507
-3,680
-0.9% -$14.4K ﹤0.01% 3140
2024
Q1 		$1.27M Sell
389,187
-3,820
-1% -$12.6K ﹤0.01% 3203
2023
Q4 		$1.38M Sell
393,007
-19,437
-5% -$60K ﹤0.01% 3177
2023
Q3 		$2.76M Sell
412,444
-1,232
-0.3% -$9.14K ﹤0.01% 2765
2023
Q2 		$3.47M Buy
413,676
+328,190
+384% +$3.23M ﹤0.01% 2703
2023
Q1 		$849K Sell
85,486
-325
-0.4% -$2.3K ﹤0.01% 3279
2022
Q4 		$597K Sell
85,811
-10
-0% -$57 ﹤0.01% 3441
2022
Q3 		$458K Sell
85,821
-4,331
-5% -$26K ﹤0.01% 3545
2022
Q2 		$360K Sell
90,152
-349,301
-79% -$1.2M ﹤0.01% 3655
2022
Q1 		$1.95M Sell
439,453
-14,662
-3% -$58.4K ﹤0.01% 3117
2021
Q4 		$1.82M Sell
454,115
-23,943
-5% -$183K ﹤0.01% 3263
2021
Q3 		$4.2M Sell
478,058
-25,006
-5% -$229K ﹤0.01% 2841
2021
Q2 		$5.7M Buy
503,064
+412,862
+458% +$4.96M ﹤0.01% 2765
2021
Q1 		$1.07M Buy
90,202
+16,838
+23% +$194K ﹤0.01% 3569
2020
Q4 		$504K Sell
73,364
-2,060
-3% -$14.5K ﹤0.01% 3726
2020
Q3 		$559K Buy
75,424
+25,802
+52% +$167K ﹤0.01% 3581
2020
Q2 		$207K Sell
49,622
-213,194
-81% -$779K ﹤0.01% 3751
2020
Q1 		$649K Buy
262,816
+6,540
+3% +$29.4K ﹤0.01% 3380
2019
Q4 		$1.49M Sell
256,276
-1,586
-0.6% -$9.16K ﹤0.01% 3259
2019
Q3 		$1.36M Sell
257,862
-38,267
-13% -$206K ﹤0.01% 3284
2019
Q2 		$1.78M Buy
296,129
+19,203
+7% +$145K ﹤0.01% 3137
2019
Q1 		$2.5M Buy
276,926
+16,165
+6% +$137K ﹤0.01% 2942
2018
Q4 		$2.16M Buy
260,761
+55,679
+27% +$571K ﹤0.01% 3003
2018
Q3 		$2.83M Buy
205,082
+13,807
+7% +$112K ﹤0.01% 3013
2018
Q2 		$1.52M Buy
191,275
+143,124
+297% +$1.14M ﹤0.01% 3331
2018
Q1 		$361K Buy
48,151
+12,290
+34% +$93.3K ﹤0.01% 3650
2017
Q4 		$244K Buy
35,861
+18,594
+108% +$122K ﹤0.01% 3751
2017
Q3 		$124K Buy
17,267
+2,268
+15% +$11.8K ﹤0.01% 3902
2017
Q2 		$70K Hold
14,999
– – ﹤0.01% 4038
2017
Q1 		$75K Buy
14,999
+675
+5% +$3.48K ﹤0.01% 4008
2016
Q4 		$77K Buy
14,324
+1,478
+12% +$8.67K ﹤0.01% 3952
2016
Q3 		$100K Buy
12,846
+480
+4% +$2.93K ﹤0.01% 3895
2016
Q2 		$70K Buy
12,366
+80
+0.7% +$447 ﹤0.01% 3956
2016
Q1 		$51K Hold
12,286
– – ﹤0.01% 4016
2015
Q4 		$83K Hold
12,286
– – ﹤0.01% 3972
2015
Q3 		$71K Buy
12,286
+1,180
+11% +$9.21K ﹤0.01% 4007
2015
Q2 		$86K Buy
+11,106
New +$95.8K ﹤0.01% 3974

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust's ALDX Position: Q1 2026 in Review

Northern Trust reduced its Aldeyra Therapeutics (ALDX) stake by 1.2% in Q1 2026, selling an estimated $20.1K and leaving 374,812 shares worth $633K. The position accounts for ﹤0.01% of the portfolio, ranked #3520.

Northern Trust first reported a position in ALDX in Q2 2015 and has held it in 44 quarters since. The position peaked at $5.7M in Q2 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Northern Trust held 374,812 shares of Aldeyra Therapeutics worth $633K as of Q1 2026.
  • Northern Trust sold 4,593 Aldeyra Therapeutics shares in Q1 2026, an estimated $20.1K.
  • Aldeyra Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3520 holding.
  • Northern Trust first reported a position in Aldeyra Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • Northern Trust's Aldeyra Therapeutics position peaked at $5.7M in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.